Ex-Biopure Head Settles SEC Blood Substitute Case
Biopure Corp.'s former head of regulatory affairs has settled with the U.S. Securities and Exchange Commission for his role in an alleged scheme to promote the company's blood substitute, despite receiving...To view the full article, register now.
Already a subscriber? Click here to view full article